118 related articles for article (PubMed ID: 16234081)
21. Preoperative PSA level significantly associated with interval to biochemical progression after radical retropubic prostatectomy.
Gonzalez CM; Roehl KA; Antenor JV; Blunt LW; Han M; Catalona WJ
Urology; 2004 Oct; 64(4):723-8. PubMed ID: 15491709
[TBL] [Abstract][Full Text] [Related]
22. Outcomes in patients with Gleason score 8-10 prostate cancer: relation to preoperative PSA level.
McGuire BB; Helfand BT; Loeb S; Hu Q; O'Brien D; Cooper P; Yang X; Catalona WJ
BJU Int; 2012 Jun; 109(12):1764-9. PubMed ID: 22017732
[TBL] [Abstract][Full Text] [Related]
23. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years.
Amling CL; Blute ML; Bergstralh EJ; Seay TM; Slezak J; Zincke H
J Urol; 2000 Jul; 164(1):101-5. PubMed ID: 10840432
[TBL] [Abstract][Full Text] [Related]
24. Invasion of seminal vesicles by adenocarcinoma of the prostate: PSA outcome determined by preoperative and postoperative factors.
Bloom KD; Richie JP; Schultz D; Renshaw A; Saegaert T; D'amico AV
Urology; 2004 Feb; 63(2):333-6. PubMed ID: 14972484
[TBL] [Abstract][Full Text] [Related]
25. The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era.
DiMarco DS; Zincke H; Sebo TJ; Slezak J; Bergstralh EJ; Blute ML
J Urol; 2005 Apr; 173(4):1121-5. PubMed ID: 15758719
[TBL] [Abstract][Full Text] [Related]
26. The outcome of patients with pathological Gleason score >or=8 prostate cancer after radical prostatectomy.
Rodriguez-Covarrubias F; Larre S; De La Taille A; Abbou CC; Salomon L
BJU Int; 2008 Feb; 101(3):305-7. PubMed ID: 17941921
[TBL] [Abstract][Full Text] [Related]
27. Time trends in case selection, stage and prostate-specific antigen recurrence after radical prostatectomy: a multicentre audit.
Winkler MH; Khan FA; Hoh IM; Okeke AA; Sugiono M; McInerney P; Boustead GB; Persad R; Kaisary AV; Gillatt DA
BJU Int; 2004 Apr; 93(6):725-9. PubMed ID: 15049980
[TBL] [Abstract][Full Text] [Related]
28. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy.
Blute ML; Bergstralh EJ; Iocca A; Scherer B; Zincke H
J Urol; 2001 Jan; 165(1):119-25. PubMed ID: 11125379
[TBL] [Abstract][Full Text] [Related]
29. Surgical and oncological outcomes in patients with preoperative PSA >20 ng/ml undergoing robot-assisted radical prostatectomy.
Zugor V; Witt JH; Heidenreich A; Porres D; Labanaris AP
Anticancer Res; 2012 May; 32(5):2091-5. PubMed ID: 22593494
[TBL] [Abstract][Full Text] [Related]
30. Radical prostatectomy and positive surgical margins: relationship with prostate cancer outcome.
De La Roca RL; Da Cunha IW; Bezerra SM; Da Fonseca FP
Int Braz J Urol; 2014; 40(3):306-15. PubMed ID: 25010296
[TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of preoperative factors in localized prostate carcinoma treated with radical prostatectomy: importance of percentage of biopsies that contain tumor and the presence of biopsy perineural invasion.
Quinn DI; Henshall SM; Brenner PC; Kooner R; Golovsky D; O'Neill GF; Turner JJ; Delprado W; Grygiel JJ; Sutherland RL; Stricker PD
Cancer; 2003 Apr; 97(8):1884-93. PubMed ID: 12673714
[TBL] [Abstract][Full Text] [Related]
32. Preoperative PSA and progression-free survival after radical prostatectomy for Stage T1c disease.
Antenor JA; Roehl KA; Eggener SE; Kundu SD; Han M; Catalona WJ
Urology; 2005 Jul; 66(1):156-60. PubMed ID: 15992903
[TBL] [Abstract][Full Text] [Related]
33. Radical prostatectomy as initial monotherapy for patients with pathologically confirmed high-grade prostate cancer.
Bahler CD; Foster RS; Bihrle R; Beck SD; Gardner TA; Sundaram CP; Masterson TA; Cheng L; Koch MO
BJU Int; 2010 May; 105(10):1372-6. PubMed ID: 19863521
[TBL] [Abstract][Full Text] [Related]
34. Does the tertiary Gleason pattern influence the PSA progression-free interval after retropubic radical prostatectomy for organ-confined prostate cancer?
van Oort IM; Schout BM; Kiemeney LA; Hulsbergen CA; Witjes JA
Eur Urol; 2005 Oct; 48(4):572-6. PubMed ID: 16046051
[TBL] [Abstract][Full Text] [Related]
35. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.
Ward JF; Slezak JM; Blute ML; Bergstralh EJ; Zincke H
BJU Int; 2005 Apr; 95(6):751-6. PubMed ID: 15794776
[TBL] [Abstract][Full Text] [Related]
36. Pathological parameters of radical prostatectomy for clinical stages T1c versus T2 prostate adenocarcinoma: decreased pathological stage and increased detection of transition zone tumors.
Jack GS; Cookson MS; Coffey CS; Vader V; Roberts RL; Chang SS; Smith JA; Shappell SB
J Urol; 2002 Aug; 168(2):519-24. PubMed ID: 12131301
[TBL] [Abstract][Full Text] [Related]
37. Tumour volume is an independent predictor of prostate-specific antigen recurrence in patients undergoing radical prostatectomy for clinically localized prostate cancer.
Nelson BA; Shappell SB; Chang SS; Wells N; Farnham SB; Smith JA; Cookson MS
BJU Int; 2006 Jun; 97(6):1169-72. PubMed ID: 16686706
[TBL] [Abstract][Full Text] [Related]
38. Anatomic site-specific positive margins in organ-confined prostate cancer and its impact on outcome after radical prostatectomy.
Blute ML; Bostwick DG; Bergstralh EJ; Slezak JM; Martin SK; Amling CL; Zincke H
Urology; 1997 Nov; 50(5):733-9. PubMed ID: 9372884
[TBL] [Abstract][Full Text] [Related]
39. Importance of margin extent as a predictor of outcome after adjuvant radiotherapy for Gleason score 7 pT3N0 prostate cancer.
Valicenti RK; Chervoneva I; Gomella LG
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1093-7. PubMed ID: 15001249
[TBL] [Abstract][Full Text] [Related]
40. Outcome and complications of radical prostatectomy in patients with PSA <10 ng/ml: comparison between the retropubic, perineal and laparoscopic approach.
Salomon L; Levrel O; Anastasiadis AG; Saint F; de La Taille A; Cicco A; Vordos D; Hoznek A; Chopin D; Abbou CC
Prostate Cancer Prostatic Dis; 2002; 5(4):285-90. PubMed ID: 12627213
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
